These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17300492)

  • 21. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
    Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
    Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation.
    Diekmann F; Campistol JM; Saval N; Gutiérrez-Dalmau A; Arellano EM; Crespo M; Rossich E; Esforzado N; Cofán F; Ricart MJ; Torregrosa JV; Oppenheimer F
    Transplantation; 2007 Aug; 84(3):429-32. PubMed ID: 17700171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed renal graft function: the influence of immunosuppression.
    Boletis J; Balitsari A; Filiopoulos V; Stamataki E; Lionaki S; Zavos G; Kostakis A
    Transplant Proc; 2005 Jun; 37(5):2054-9. PubMed ID: 15964337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
    Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
    Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.
    Baczkowska T; Perkowska-Ptasińska A; Sadowska A; Lewandowski Z; Nowacka-Cieciura E; Cieciura T; Pazik J; Lewandowska D; Mroz A; Urbanowicz A; Nazarewski S; Danielewicz R
    Transplant Proc; 2005 Mar; 37(2):773-5. PubMed ID: 15848527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of donor antigen-specific hyporeactivity with allogeneic microchimerism in kidney and lung recipients.
    Reinsmoen NL; McSherry C; Chavers B; Hertz MI; Matas AJ
    Pediatr Nephrol; 1995; 9 Suppl():S35-9. PubMed ID: 7492484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcineurin inhibitor-free immunosuppression in renal transplantation.
    Parada B; Mota A; Nunes P; Macário F; Pratas J; Bastos C; Figueiredo A
    Transplant Proc; 2005; 37(6):2759-61. PubMed ID: 16182803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excellent results with calcineurin inhibitor-free initial immunosuppression in old recipients of old kidneys.
    Bösmüller C; Ollinger R; Mark W; Brandacher G; Schneeberger S; Cakar F; Bonatti H; Margreiter R
    Transplant Proc; 2005 Mar; 37(2):881-3. PubMed ID: 15848563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
    Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
    González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A
    Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients.
    Reinsmoen NL; Kaufman D; Matas A; Sutherland DE; Najarian JS; Bach FH
    Transplantation; 1990 Nov; 50(5):783-90. PubMed ID: 2146784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. After discontinuation of calcineurin inhibitors, tapering of mycophenolate mofetil further impairs donor-directed cytotoxicity.
    van Besouw NM; van de Wetering J; van der Mast BJ; de Kuiper R; Baan CC; Weimar W
    Clin Transplant; 2008; 22(2):129-35. PubMed ID: 18339130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4+CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients.
    Velthuis JH; Mol WM; Weimar W; Baan CC
    Am J Transplant; 2006 Dec; 6(12):2955-64. PubMed ID: 17294523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients.
    Webster AC;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S75-84. PubMed ID: 17316285
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of transfusions and acute rejection on posttransplantation donor antigen-specific responses in two study populations. Cooperative Clinical Trial in Transplantation Research Group.
    Reinsmoen NL; Matas AJ; Donaldson L; Carter S
    Transplantation; 1999 Mar; 67(5):697-702. PubMed ID: 10096524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity.
    Jackson A; McSherry C; Butters K; Diko M; Almond PS; Matas AJ; Reinsmoen NL
    Hum Immunol; 1997 Jul; 55(2):148-53. PubMed ID: 9361966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential mixed lymphocyte culture after kidney transplantation: induction of tolerance or sensitization.
    Creemers P; Du Toit E; Cassidy MJ; Kahn D
    Nephron; 1997; 75(2):166-70. PubMed ID: 9041536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.